Sharing findings and discoveries is essential for the advancement of science. If research results are valid and reliable, they are published in journals read by the members of the international scientific community, so that everyone can learn from and build on these achievements.
In 2015, our researchers published more than 1,500 scientific papers, confirming the importance of their studies as well as the validity of our selection process and funding decisions. Each of these contributes to advancing our knowledge of cancer and to eventually making cancer more curable.
Our researchers have published their results in some of the most respected, authoritative and selective scientific journals.
Some of the most important studies are announced to the general public through our institutional channels and with collaboration from the media, so that all who support us can learn how their help has paid off.
Below is a sample of the most significant results published in 2015 by our researchers.
Potential new treatments for hairy cell leukemia
Published in: New England Journal of Medicine
Authors: Brunangelo Falini et al.
Brunangelo Falini and colleagues at the University of Perugia have identified a genetic mutation, and a drug targeted against the mutation, in the previously incurable hairy cell leukemia. read more (in Italian) ›
Discovery of DNA mutations that make late stage colon cancer resistant to treatment
Published in: Nature IF: 42,351
Authors: Livio Trusolino, Andrea Bertotti et al., IRCC Candiolo – Fondazione Piemontese per la Ricerca sul Cancro Onlus (FPRC)
When detected late, colon cancer has few treatment options, often based on the use of monoclonal antibodies aimed at targets within the tumor. Analyzing the DNA of tumors from about 200 patients, researchers have discovered characteristics of the genome associated with resistance to treatments. These findings may help delineate new therapeutic avenues for colorectal cancer based on potentially actionable genomic alterations. read more (in Italian) ›
Motherhood after breast cancer thanks to an ovary-protecting hormone
Published in: Jama IF: 35,289
Authors: Lucia Del Mastro et al., Ospedale San Martino-Istituto per la ricerca sul cancro, Genoa
Breast cancer treatment can lead to the loss of ovarian function and to early menopause, making it impossible to bear children. An Italian study validates a new strategy to reduce this risk: a woman’s eggs can be protected during chemotherapy by using the synthetic hormone triptorelin to put her ovaries at rest. read more (in Italian) ›
PTX3: the molecule that “defuels” tumors
Published in: Cell IF: 33,116
Authors: Alberto Mantovani et al., Istituto clinico Humanitas, Rozzano (MI)
This study explains how tumors can be deprived of fuel by the molecule pentraxin (PTX3), identified two decades ago. Researchers have discovered that PTX3 is fundamental to preventing the spread of cancer: without it, the tumor is free to recruit macrophage cells from the immune system, which recharge the tumor promoting growth and genetic instability. read more (in Italian) ›
Another drug for ovarian cancer
Published in: The Lancet Oncology IF: 24,725
Authors: Sandro Pignata, Francesco Perrone et al., Istituto nazionale tumori – Fondazione Pascale, Napoli
Resistance to standard chemotherapy in ovarian cancer patients can be reduced by adding a drug called pazopanib. Even though the new treatment causes more side effects, these are manageable and the progression-free survival of patients is significantly increased. read more (in Italian) ›
New details on the molecular circuits of intestinal tumors
Published in: Cell Stem Cell IF: 22,151
Authors: Diego Pasini et al., Istituto europeo di oncologia, Milan
We usually think of tumors in terms of genetic mutations, but even unaltered genes performing their standard functions can contribute to the growth of cancer. This occurs in intestinal tumors with the protein complex PRC1: researchers have demonstrated that PRC1 activity is not only crucial to the functioning of normal intestinal stem cells, but if alterations in other genes are present, it can favor tumor development. read more (in Italian) ›
All the genes controlled by YAP, a cancer “master switch”
Published in: Nature Cell Biology IF: 20,058
Authors: Stefano Piccolo, Michelangelo Cordenonsi et al., University of Padua
A sophisticated genome analysis technique has produced a detailed map of the genes controlled by YAP, one of the critical human oncogenes involved in the onset of many forms of cancer. read more (in Italian) ›
How to starve a tumor
Published in: Cell Metabolism IF: 16,747
Authors: Antonio Moschetta et al., IRCCS Istituto oncologico Giovanni Paolo II, Bari
Tumor cells grow faster than healthy cells, using the cholesterol available in the body. This study focuses on the LXR molecule and its ability to induce the elimination or synthesis of cholesterol, depending on the context: the proliferation of cancer cells can be blocked using an “agonist” molecule that stimulates LXR activity. read more (in Italian) ›
A new discovery for kidney cancer at San Raffaele
Published in: Journal of Clinical Investigation IF: 13,262
Authors: Giovanni Tonon et al., IRCCS Ospedale San Raffaele, Milan
Researchers have discovered that the JARID1C gene plays a crucial role in DNA assembly. Because the gene is inactivated in unhealthy cells, the DNA is “looser,” with an abnormal quantity of RNA molecules free to circulate. This RNA can then damage the DNA and cause genomic instability, which then promotes tumor development. read more (in Italian) ›
Some progress against glioblastoma
Published in: Genome Biology IF: 10,81
Authors: Angela Gallo et al., IRCCS Ospedale pediatrico Bambin Gesù, Rome
Both the sequence and the amount of many microRNAs (small molecules involved in gene regulation) are controlled by the ADAR2 enzyme in the brain. ADAR2 is inactive in glioblastoma, a highly aggressive tumor: by reactivating it within the tumor cells, the functional properties of altered microRNAs can be corrected, thus restoring the gene regulation present in healthy cells. read more (in Italian) ›
A new marker for liver cancer
Published in: Journal of Hepatology IF: 11,336
Authors: Amedeo Columbano, Silvia Giordano et al., University of Cagliari and IRCC Candiolo – Fondazione Piemontese per la Ricerca sul Cancro Onlus (FPRC)
A better understanding of the role of the HAO2 gene in the growth of liver tumors has led researchers to consider its expression as a useful diagnostic marker for identifying even small pre-cancerous lesions, and as a prognostic marker given that the level of HAO2 is inversely associated with the malignancy’s aggressiveness. read more (in Italian) ›